Hepatic Arterial Infusion combined with Apatinib and Camrelizumab

COMBINATION_PRODUCT2 trials

Sponsors

Sun Yat-sen University

Conditions

C-staged Hepatocellular Carcinoma in BCLC Classification

Phase 2

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

Sun Yat-sen UniversityC-staged Hepatocellular Carcinoma in BCLC Classification

Start: 2020-04-13End: 2025-12-31Target: 47Updated: 2023-09-13

Phase 3

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

Sun Yat-sen UniversityC-staged Hepatocellular Carcinoma in BCLC Classification

Start: 2022-06-15End: 2025-06-01Target: 140Updated: 2022-06-16

Related Papers

The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma.

2024-11-192 citations

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.

2023-10-2795 citations

Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).

Journal of Clinical Oncology2022-06-0114 citations